Zosano Pharma Corporation: Chapter 11 case summary
ElevenFlo ·
Zosano Pharma is in post-confirmation liquidation, with its liquidating trust administering claims and distributions under a plan effective since December 2022. The September 2026 post-confirmation report Dkt. 529 anticipated a final decree application by December 31, 2026 and reported payments equal to 21% of allowed general unsecured claims.
Zosano Pharma is in post-confirmation liquidation under a plan that became effective on December 7, 2022, following confirmation on November 22, 2022, as stated in the effective-date notice Dkt. 308. Its liquidating trust is administering the estate and distributions.
Zosano filed for Chapter 11 on June 1, 2022. The clinical-stage drug developer had incurred substantial losses while pursuing M207, a migraine treatment delivered through a microneedle patch. According to the first-day declaration Dkt. 15, the FDA twice declined to approve its application, and the additional clinical work required after the February 2022 decision would take at least eight months and significant expense. A prepetition search for strategic alternatives produced interest in discrete assets, and Zosano entered bankruptcy intending to sell assets and wind down.
The court authorized an asset sale Dkt. 164 in August 2022 and confirmed the liquidation plan Dkt. 294 in November. In its report for the quarter ended September 30, 2026 Dkt. 529, filed October 29, the liquidating trust reported $4,116,027 in cumulative cash disbursements since effectiveness. It reported $1,706,852 paid on $7,982,348 of allowed general unsecured claims, or 21%, and $727,714 paid on $727,714 of allowed administrative claims. The report was not final and anticipated an application for a final decree by December 31, 2026.
Sources
- Dkt. 15First Day DeclarationFiled Jun 2, 2022Jun 2, 2022
- Dkt. 164Order (I) Authorizing the Sale of Assets of the Debtor Free and Clear of All Liens, Claims, Encumbrances, and Interests; (II) Approving the Final Asset Purchase Agreement; (III) Authorizing the Assumption and Assignment of Certain Executory Contracts and Unexpired Leases; and (IV) Granting Related ReliefFiled Aug 8, 2022Aug 8, 2022
- Dkt. 294Findings of Fact, Conclusions of Law, and Order Confirming the Second Amended Chapter 11 Plan of Liquidation of Zosano Pharma CorporationFiled Nov 22, 2022Nov 22, 2022
- Dkt. 308Notice of (I) Confirmation and Effective Date of the Amended Chapter 11 Plan of Liquidation of Zosano Pharma Corporation and (II) Deadline Under the Plan and Confirmation Order to File Professional Fee Claims, Administrative Claims and Rejection Claims (Filed by Zosano Pharma Corporation)Filed Dec 8, 2022Dec 8, 2022
- Dkt. 529Quarterly Post-Confirmation ReportFiled Oct 29, 2026Oct 29, 2026